Drug Trial Radar · NCT05419011
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
186
Planned (sponsor's estimate)
Start
May 8, 2023
Primary completion
Jul 1, 2027
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jun 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and cancer cells. Injecting these substances may cause the immune system to develop a defense against cancer that recognizes and destroys any precancer and cancer cells that produce these proteins in the future. N-803 may increase immune responses to other vaccines. Giving Tri-Ad5 in combination with immune enhancing N-803 may lower the chance of developing colon and other cancers in participants with Lynch syndrome.
Conditions
- Colorectal Carcinoma
- Colorectal Neoplasm
- Lynch Syndrome
Interventions
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5Biological
Given SC
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
ColonoscopyProcedure
Undergo SOC colonoscopy
Nogapendekin AlfaDrug
Given nogapendekin alfa inbakicept (N-803) SC
Placebo AdministrationDrug
Given SC
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative incidence rate of the composite endpoint of adenomas (tubular, tubulovillous and serrated), advanced adenomas and colon cancerTime frame: At 104 weeks
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital in Arizona
Phoenix, Arizona
University of Arizona Cancer Center - Prevention Research Clinic
Tucson, Arizona
UCSF Medical Center-Parnassus
San Francisco, California
UCHealth University of Colorado Hospital
Aurora, Colorado
Northwestern University
Chicago, Illinois
University of Kansas Cancer Center
Kansas City, Kansas
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Mayo Clinic in Rochester
Rochester, Minnesota
Cleveland Clinic Foundation
Cleveland, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Fox Chase Cancer Center
Philadelphia, Pennsylvania
UT MD Anderson Cancer Center
Houston, Texas
University of Puerto Rico
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.